JNJ-42756493, JNJ-42756493, JNJ-42756493
42756493CAN2002
Phase 2 small_molecule active
Quick answer
JNJ-42756493, JNJ-42756493, JNJ-42756493 for Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations. is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active